|
Market Closed -
Nasdaq
16:00:00 2026-09-18 EDT
|
5-day change | 1st Jan Change | ||
| 78.09 USD | -1.19% |
|
-1.54% | -4.63% |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
Geographical Revenue Distribution History
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
Pharmaceutical Products | ||||||||
Therapeutics | 57.03M | 25.82M | 17.45M | 183M | 451M | |||
Total Assets | 179M | 228M | 265M | 377M | 562M | |||
Interest Expense | - | -2.2M | -3.35M | -7.85M | -8.94M | |||
Income Tax Expense | 55K | -4K | - | - | 2.06M | |||
CAPEX | -586K | -506K | -1.5M | -1.57M | -9.86M | |||
EBT | -13.77M | -62.1M | -136M | -116M | -64.36M | |||
D&A | 312K | 325K | 877K | 1.22M | 1.82M | |||
Operating Income | -12.16M | -62.71M | -143M | -121M | -70.97M | |||
Net Income | -13.83M | -62.09M | -136M | -116M | -66.42M |
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
United States | 57.03M | 25.82M | 17.45M | 183M | 451M | |||
Total Assets | 179M | 228M | 265M | 377M | 562M | |||
Interest Expense | - | -2.2M | -3.35M | -7.85M | -8.94M | |||
Income Tax Expense | 55K | -4K | - | - | 2.06M | |||
D&A | 312K | 325K | 877K | 1.22M | 1.82M | |||
CAPEX | -586K | -506K | -1.5M | -1.57M | -9.86M | |||
Net Income | -13.83M | -62.09M | -136M | -116M | -66.42M | |||
EBT | -13.77M | -62.1M | -136M | -116M | -64.36M | |||
Operating Income | -12.16M | -62.71M | -143M | -121M | -70.97M |
- Stock Market
- Stocks
- TARS Stock
- Financials Tarsus Pharmaceuticals, Inc.
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
